Ultrastructural changes to rabbit fibrin and platelets due to aspartame - PubMed (original) (raw)
Ultrastructural changes to rabbit fibrin and platelets due to aspartame
E Pretorius et al. Ultrastruct Pathol. 2007 Mar-Apr.
Abstract
The coagulation process, including thrombin, fibrin, as well as platelets, plays an important role in hemostasis, contributing to the general well-being of humans. Fibrin formation and platelet activation are delicate processes that are under the control of many small physiological events. Any one of these many processes may be influenced or changed by external factors, including pharmaceutical or nutritional products, e.g., the sweetener aspartame (L-aspartyl-L-phenylalanine methyl ester). It is known that phenylalanine is present at position P(9) and aspartate at position P(10) of the alpha-chain of human fibrinogen, and plays an important role in the conversion of fibrinogen to fibrin by the catalyst alpha-thrombin. The authors investigate the effect of aspartame on platelet and fibrin ultrastructure, by using the rabbit animal model and the scanning electron microscope. Animals were exposed to 34 mg/kg of aspartame 26x during a 2-month period. Aspartame-exposed fibrin networks appeared denser, with a thick matted fine fiber network covering thick major fibers. Also, the platelet aggregates appeared more granular than the globular control platelet aggregates. The authors conclude by suggesting that aspartame usage may interfere with the coagulation process and might cause delayed fibrin breakup after clot formation. They suggest this, as the fibrin networks from aspartame-exposed rabbits are more complex and dense, due to the netlike appearance of the minor, thin fibers. Aspartame usage should possibly be limited by people on anti-clotting medicine or those with prone to clot formation.
Similar articles
- Comparative ultrastructural analyses of platelets and fibrin networks using the murine model of asthma.
Pretorius E, Ekpo OE, Smit E. Pretorius E, et al. Exp Toxicol Pathol. 2007 Oct;59(2):105-14. doi: 10.1016/j.etp.2007.02.011. Epub 2007 Jun 27. Exp Toxicol Pathol. 2007. PMID: 17600694 - Comparative ultrastructural analyses of mouse, rabbit, and human platelets and fibrin networks.
Pretorius E, Humphries P, Ekpo OE, Smit E, van der Merwe CF. Pretorius E, et al. Microsc Res Tech. 2007 Sep;70(9):823-7. doi: 10.1002/jemt.20482. Microsc Res Tech. 2007. PMID: 17576129 - Ultrastructural morphology of platelets and fibrin networks of lactating and non-pregnant rabbits.
Humphries P, Smit E, Pretorius E. Humphries P, et al. Anat Histol Embryol. 2008 Aug;37(4):285-8. doi: 10.1111/j.1439-0264.2008.00842.x. Epub 2008 Feb 14. Anat Histol Embryol. 2008. PMID: 18279493 - Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies.
Magnuson BA, Burdock GA, Doull J, Kroes RM, Marsh GM, Pariza MW, Spencer PS, Waddell WJ, Walker R, Williams GM. Magnuson BA, et al. Crit Rev Toxicol. 2007;37(8):629-727. doi: 10.1080/10408440701516184. Crit Rev Toxicol. 2007. PMID: 17828671 Review. - Thrombin generation and fibrin clot structure.
Wolberg AS. Wolberg AS. Blood Rev. 2007 May;21(3):131-42. doi: 10.1016/j.blre.2006.11.001. Epub 2007 Jan 8. Blood Rev. 2007. PMID: 17208341 Review.
Cited by
- Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB. Pretorius E, et al. Cardiovasc Diabetol. 2022 Aug 6;21(1):148. doi: 10.1186/s12933-022-01579-5. Cardiovasc Diabetol. 2022. PMID: 35933347 Free PMC article. - Eryptosis as a marker of Parkinson's disease.
Pretorius E, Swanepoel AC, Buys AV, Vermeulen N, Duim W, Kell DB. Pretorius E, et al. Aging (Albany NY). 2014 Oct;6(10):788-819. doi: 10.18632/aging.100695. Aging (Albany NY). 2014. PMID: 25411230 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources